Table 1 Demographic and clinical characteristics of patients in the derivation cohort
N (%) | All (n = 812, 100%) | Low CTC (n = 332, 39.7%) | Intermediate CTC (n = 354, 43.6%) | High CTC (n = 126, 15.5%) | P value |
|---|---|---|---|---|---|
Age, years* | 54.0 ± 10.7 | 53.8 ± 10.5 | 54.7 ± 10.9 | 55.1 ± 10.6 | 0.084 |
Gender, Male | 554 (68.2) | 232 (69.8) | 242 (68.3) | 80 (63.4) | 0.422 |
HBV (+) | 310 (38.1) | 134 (40.3) | 139 (39.2) | 37 (29.3) | 0.082 |
ASA score ≥ 2 | 187 (23.0) | 82 (24.6) | 77 (21.7) | 28 (22.2) | 0.639 |
Cirrhosis | 343 (42.2) | 154 (46.3) | 143 (40.3) | 46 (36.5) | 0.104 |
Child-Pugh grade B | 44 (5.4) | 18 (5.4) | 20 (5.6) | 6 (4.7) | 0.931 |
Preoperative platelet counts, ×109/L* | 192.6 ± 72.6 | 179.7 ± 74.0 | 198.6 ± 71.9 | 210.1 ± 65.2 | < 0.001 |
Preoperative NLR* | 2.5 (1.9–3.6) | 2.1 (1.6–2.8) | 2.9 (2.1–4.1) | 3.0 (2.2–4.1) | < 0.001 |
Preoperative CA 19 − 9, U/mL* | 39.5 (15.7–247.4) | 28.8 (14.7–94.6) | 41.2 (14.4–236.1) | 378.9 (25.7–1000.0) | < 0.001 |
Preoperative CEA (ng/mL), n(%) | < 0.001 | ||||
Low | 603 (74.3) | 332 (100.0) | 271 (76.5) | 0 (0.0) | |
High | 209 (25.7) | 0 (0.0) | 83 (23.5) | 126 (100.0) | |
Tumor Burden Score | < 0.001 | ||||
Low | 415 (51.1) | 332 (100.0) | 83 (23.5) | 0 (0.0) | |
High | 397 (48.9) | 0 (0.0) | 271 (76.5) | 126 (100.0) | |
Maximum tumor size, cm* | 6.3 ± 3.5 | 3.7 ± 1.2 | 7.9 ± 3.9 | 8.4 ± 2.0 | < 0.001 |
Tumor number, multiple | 82 (10.0) | 30 (9.0) | 37 (10.4) | 15 (11.9) | 0.633 |
Tumor differentiation | 0.102 | ||||
Well | 78 (9.6) | 32 (9.6) | 40 (11.3) | 6 (4.8) | |
Poor to moderate | 734 (90.4) | 300 (90.4) | 314 (88.7) | 120 (95.2) | |
Type of resection, Major | 315 (38.7) | 97 (29.2) | 154 (43.5) | 64 (50.7) | < 0.001 |
Macrovascular invasion | 107 (13.1) | 30 (9.0) | 55 (15.5) | 22 (17.4) | 0.013 |
Microvascular invasion | 125 (15.3) | 46 (13.8) | 65 (18.3) | 14 (11.1) | 0.092 |
Resection margin status | 0.011 | ||||
R0 | 733 (90.3) | 312 (94.0) | 309 (87.3) | 112 (88.8) | |
R1 | 79 (9.7) | 20 (6.0) | 45 (12.7) | 14 (11.2) | |
Postoperative adjuvant therapy | 255 (31.4) | 100 (30.1) | 119 (33.6) | 36 (28.5) | 0.466 |
AJCC staging system8th | 0.007 | ||||
I | 437 (53.8) | 204 (61.4) | 175 (49.4) | 58 (46.0) | |
II | 163 (20.1) | 63 (19.0) | 74 (20.9) | 26 (20.6) | |
III | 189 (23.3) | 60 (18.1) | 91 (25.8) | 38 (30.2) | |
IV | 23 (2.8) | 5 (1.5) | 14 (3.9) | 4 (3.2) | |
Postoperative 30-day complication | 343 (42.2) | 128 (38.5) | 157 (44.3) | 58 (46.0) | 0.198 |
Minor morbidity | 274 (33.7) | 104 (31.3) | 122 (34.4) | 48 (38.1) | 0.365 |
Major morbidity | 69 (8.5) | 24 (7.2) | 35 (9.9) | 10 (7.9) | 0.445 |